Catalent, Inc. has appointed Manja Boerman, Ph.D., President, Cell & Gene Therapy, effective June 1, 2020. In this new role, Dr. Boerman will lead all of Catalent’s cell & gene therapy businesses worldwide. Dr. Boerman will continue to report to Karen Flynn, Catalent’s President of Biologics and Chief Commercial Officer.   Pete Buzy, who has led the Catalent Gene Therapy business since the company’s acquisition of Paragon Bioservices in May 2019, will be retiring but will remain with t...